PPARγ is a target for the treatment of metabolic diseases like diabetes mellitus and obesity. Thiazolidinediones (TZDs), a class of drugs used to treat type 2 diabetes, are PPARγ agonists. They improve insulin sensitivity by modulating the genes involved in glucose and lipid metabolism. However, the use of TZDs is associated with side effects such as weight gain and cardiovascular risks.
